Chronic kidney disease and aging: dissecting the p53/p21 pathway as a therapeutic target
Biogerontology · 2025
DOI: 10.1007/s10522-024-10173-z ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biogerontology, 2025. Verfasst von Kavita Goyal und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, Graphic Era (Deemed to Be University), Clement Town, Dehradun, 248002, India. Hauptthemen laut MEDLINE: Aging, Cellular Senescence, Cyclin-Dependent Kinase Inhibitor p21, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 232 Literaturangaben.
Abstract (Originalsprache)
Chronic kidney diseases (CKD) are a group of multi-factorial disorders that markedly impair kidney functions with progressive renal deterioration. Aging contributes to age-specific phenotypes in kidneys, which undergo several structural and functional alterations, such as a decline in regenerative capacity and increased fibrosis, inflammation, and tubular atrophy, all predisposing them to disease and increasing their susceptibility to injury while impeding their recovery. A central feature of these age-related processes is the activation of the p53/p21 pathway signaling. The pathway is a key player in cellular senescence, apoptosis, and cell cycle regulation, which are all key to maintaining the health of the kidney. P53 is a transcription factor and a tumor suppressor protein that responds to cell stress and damage. Persistent activation of cell p53 can lead to the expression of p21, an inhibitor of the cell cycle known as a cyclin-dependent kinase. This causes cells to cease dividing and leads to senescence, where cells can no longer increase. The accumulation of senescent cells in the aging kidney impairs kidney function by altering the microenvironment. As the number of senescent cells increases, the capacity of the kidney to recover from injury decreases, accelerating the progression of end-stage renal disease. This article review extensively explores the relationship between the p53/p21 pathway and cellular senescence within an aging kidney and the emerging therapeutic strategies that target it to overcome the impacts of cellular senescence on CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotechnology, Graphic Era (Deemed to Be University), Clement Town, Dehradun, 248002, India.
- Department of Pharmaceutical Sciences, Pharmacy Program, Batterjee Medical College, P.O. Box 6231, 21442, Jeddah, Saudi Arabia.
- Department of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam Bin Abdulaziz University, 11942, Al Kharj, Saudi Arabia.
- Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India.
- Department of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to Be University), Bangalore, Karnataka, India.
- Department of Allied Healthcare and Sciences, Vivekananda Global University, Jaipur, Rajasthan, 303012, India.
Zitieren
APA
Goyal, K., Afzal, M., Altamimi, A. S. A., Babu, M. A., Ballal, S., Kaur, I., Kumar, S., Kumar, M. R., Chauhan, A. S., Ali, H., Shahwan, M., & Gupta, G. (2025). Chronic kidney disease and aging: dissecting the p53/p21 pathway as a therapeutic target. Biogerontology. https://doi.org/10.1007/s10522-024-10173-z
Vancouver
Goyal K, Afzal M, Altamimi ASA, Babu MA, Ballal S, Kaur I, et al. Chronic kidney disease and aging: dissecting the p53/p21 pathway as a therapeutic target. Biogerontology. 2025. doi:10.1007/s10522-024-10173-z
BibTeX
@article{Goyal2025,
author = {Goyal, Kavita and Afzal, Muhammad and Altamimi, Abdulmalik Saleh Alfawaz and Babu, M Arockia and Ballal, Suhas and Kaur, Irwanjot and Kumar, Sachin and Kumar, M Ravi and Chauhan, Ashish Singh and Ali, Haider and Shahwan, Moyad and Gupta, Gaurav},
title = {Chronic kidney disease and aging: dissecting the p53/p21 pathway as a therapeutic target},
journal = {Biogerontology},
year = {2025},
doi = {10.1007/s10522-024-10173-z}
}
EUVIMED